Efficacy and safety of bazedoxifene for postmenopausal osteoporosis

Hisaya Kawate, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have favorable effects on bone and the lipid profile w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kawate H, Takayanagi R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	SERM osteoporosis estrogen receptor nonvertebral fracture endometrium Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/a20acec5398f45c3a04962dcb0ec23be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a20acec5398f45c3a04962dcb0ec23be
record_format	dspace
spelling	oai:doaj.org-article:a20acec5398f45c3a04962dcb0ec23be2021-12-02T08:10:37ZEfficacy and safety of bazedoxifene for postmenopausal osteoporosis1178-1998https://doaj.org/article/a20acec5398f45c3a04962dcb0ec23be2011-06-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-bazedoxifene-for-postmenopausal-osteoporosis-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Hisaya Kawate, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues. Two large Phase III clinical trials showed that bazedoxifene, as well as raloxifene, increased bone mineral density, decreased levels of bone turnover markers, and significantly reduced the risk of new vertebral fractures in postmenopausal women compared with placebo. Although the incidence of nonvertebral fractures with bazedoxifene or raloxifene did not differ significantly from that with placebo, a post hoc analysis of a subgroup of women at higher fracture risk revealed that bazedoxifene significantly reduced the nonvertebral fracture risk relative to placebo and raloxifene. Bazedoxifene also improved the lipid profile by reducing the serum concentrations of total cholesterol and low-density lipoprotein cholesterol, with an increase in the serum level of high-density lipoprotein cholesterol. The incidences of vasodilatation (hot flushes), leg cramps, and venous thromboembolic events were significantly higher with bazedoxifene and raloxifene compared with placebo. There was no evidence of endometrial and breast stimulation with bazedoxifene. Taking advantage of the favorable effects of bazedoxifene on the breast and endometrium, the pairing of bazedoxifene with conjugated estrogens is under investigation for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. A Phase III trial showed that combination therapy of bazedoxifene and conjugated estrogens significantly increased bone mineral density and decreased bone turnover markers, with relief of hot flushes and improvement of vaginal atrophy. This article reviews the clinical efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis.Keywords: selective estrogen receptor modulators, osteoporosis, estrogen receptor, nonvertebral fracture, endometriumKawate HTakayanagi RDove Medical PressarticleSERMosteoporosisestrogen receptornonvertebral fractureendometriumGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 151-160 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	SERM osteoporosis estrogen receptor nonvertebral fracture endometrium Geriatrics RC952-954.6
spellingShingle	SERM osteoporosis estrogen receptor nonvertebral fracture endometrium Geriatrics RC952-954.6 Kawate H Takayanagi R Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
description	Hisaya Kawate, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues. Two large Phase III clinical trials showed that bazedoxifene, as well as raloxifene, increased bone mineral density, decreased levels of bone turnover markers, and significantly reduced the risk of new vertebral fractures in postmenopausal women compared with placebo. Although the incidence of nonvertebral fractures with bazedoxifene or raloxifene did not differ significantly from that with placebo, a post hoc analysis of a subgroup of women at higher fracture risk revealed that bazedoxifene significantly reduced the nonvertebral fracture risk relative to placebo and raloxifene. Bazedoxifene also improved the lipid profile by reducing the serum concentrations of total cholesterol and low-density lipoprotein cholesterol, with an increase in the serum level of high-density lipoprotein cholesterol. The incidences of vasodilatation (hot flushes), leg cramps, and venous thromboembolic events were significantly higher with bazedoxifene and raloxifene compared with placebo. There was no evidence of endometrial and breast stimulation with bazedoxifene. Taking advantage of the favorable effects of bazedoxifene on the breast and endometrium, the pairing of bazedoxifene with conjugated estrogens is under investigation for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. A Phase III trial showed that combination therapy of bazedoxifene and conjugated estrogens significantly increased bone mineral density and decreased bone turnover markers, with relief of hot flushes and improvement of vaginal atrophy. This article reviews the clinical efficacy and safety of bazedoxifene in the treatment of postmenopausal osteoporosis.Keywords: selective estrogen receptor modulators, osteoporosis, estrogen receptor, nonvertebral fracture, endometrium
format	article
author	Kawate H Takayanagi R
author_facet	Kawate H Takayanagi R
author_sort	Kawate H
title	Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
title_short	Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
title_full	Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
title_fullStr	Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
title_full_unstemmed	Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
title_sort	efficacy and safety of bazedoxifene for postmenopausal osteoporosis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/a20acec5398f45c3a04962dcb0ec23be
work_keys_str_mv	AT kawateh efficacyandsafetyofbazedoxifeneforpostmenopausalosteoporosis AT takayanagir efficacyandsafetyofbazedoxifeneforpostmenopausalosteoporosis
_version_	1718398618103185408

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis

Ejemplares similares